Advanced in Glucose-6-Phosphate Translocase Deficiency

Sandra M. Sirrs

Level 4 2775 Laurel Street, V5Z 1M9, 
Vancouver, BC, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Glucose-6-Phosphate Translocase Deficiency
Level 4 2775 Laurel Street, V5Z 1M9, 
Vancouver, BC, CA 
OverviewLocationsClinical Research

Overview

Sandra Sirrs practices in Vancouver, Canada. Ms. Sirrs is rated as an Advanced expert by MediFind in the treatment of Glucose-6-Phosphate Translocase Deficiency. Her top areas of expertise are Fabry Disease, Krabbe Disease, Glucose-6-Phosphate Translocase Deficiency, Splenectomy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 71 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Glucose-6-Phosphate Translocase Deficiency.

Gender
Female

Locations

Level 4 2775 Laurel Street, V5Z 1M9, Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Canadian Fabry Disease Initiative National Registry: Outcomes of Rare Disease Therapeutics and Cardiovascular Risk Factor Modification
Canadian Fabry Disease Initiative National Registry: Outcomes of Rare Disease Therapeutics and Cardiovascular Risk Factor Modification
Enrollment Status: Recruiting
Publish Date: February 15, 2024
Intervention Type: Other
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 3
View 2 Less Clinical Trial

71 Total Publications

Investigating the role of a novel hemizygous FAAH2 variant in neurological and metabolic disorders.
Investigating the role of a novel hemizygous FAAH2 variant in neurological and metabolic disorders.
Journal: Gene
Published: May 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sirrs's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile